[1]王雪鹃,张梅颖,林保和.肿瘤血管活性肠肽受体显像[J].国际放射医学核医学杂志,2001,25(2):65-69.
 WANG Xue-juan,ZHANG Mei-ying,LIN Bao-he.Tumor imaging of vasoactive intestinal peptide receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(2):65-69.
点击复制

肿瘤血管活性肠肽受体显像(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
25
期数:
2001年第2期
页码:
65-69
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Tumor imaging of vasoactive intestinal peptide receptor
作者:
王雪鹃 张梅颖 林保和
100036 北京, 北京大学临床肿瘤医院核医学科
Author(s):
WANG Xue-juan ZHANG Mei-ying LIN Bao-he
Department of Nuclear Medicine, Affiliated Tumor Hospital, Peking University, Beijing 100036, China
关键词:
肿瘤血管活性肠肽受体显像
Keywords:
tumorvasoactive intestinal peptidereceptor imaging
分类号:
R817.4
摘要:
血管活性肠肽(VIP)是一种由28个氨基酸组成具有多种功能的神经递质,能通过其受体调节正常及肿瘤细胞的增殖和分化。VPAC(VIP受体)广泛存在于各种正常和肿瘤组织中,但其在肿瘤组织中的表达密度远大于正常组织,这为放射性核素标记的血管活性肠肽受体显像奠定基础。此种显像已应用于多种肿瘤的诊断、分期、治疗方案选择与预后评价。
Abstract:
Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino acid peptide with a wide range of biological activities. It can regular the cellular proliferaton and differentiation through its receptors. Recent reports suggest that VIP receptors are expressed on a variety of malignant tumor cells and that the receptor density is higher than normal tissue. The high expression of VIP receptors provided the basis for the clinical use of radiolabeled VIP for the in vivo localization of the malignant tumors. The imaging has been used for diagnosis,staging, therapy strategy and prognosis of wide range of tumors.

参考文献/References:

[1] Said SI,M utt V.Polupeptide with broad biological activity:Isolation from the small intestinal[J].Science,1970,69:1217-1218.
[2] HarmarAJ,Arimura A.International union of pharmacology Ⅹ Ⅷ.nomenclature of receptor for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide[J].Pharmacol Rev,1998,50(2):265-270.
[3] Fahrnkrug J.Glycine-extended processing intermediate of proVIP:A new bioactive form of VIP in the rat[J].Biomed Res,1992,13:19-23.
[4] Bolin DR,Cottrell J.Strycture-activity studies on the vasoactive intestinal peptide pharmacophore[J].Int J Pritein Res,1995,46:279-289.
[5] Wulff B,Moller-Knusen S.The C-terminal part of VIP is importan for receptor binding and activation,as evidenced by chimeric constructs of VIP/secretin[J].FEBS Lett,1997,413(3):405-408.
[6] Usdin TB,Bonner TI.Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions[J].Endocrinology,1994,35(6):2662-2680.
[7] Gaudin P,Couvineau A.Role of cysteine residues in the N-terminal extracellular domain of the humun VIP1 receptor for ligand:A site-directed mutagenesis study[J].Ann NY Acad Sci,1996,805:585-589.
[8] Nicol P,Du K.Site-directed mutagenesis of human VIP1 versus VIP2 receptors[J].Ann N Y Acad Sci,1998,865:378-381.
[9] Nicol P,Du K.Site-directed mutagenesis of humann vasoactive intestinal peptide receptor subtypes VIP1 and VIP2:evidence for difference in the structure-function relationship[J].J Phannacol Exp Ther,1998,284(2):744-750.
[10] Sreedharan SP,Patel DR.Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor[J].Biochem Biophys Res Commun,1993,193(2):546-553.
[11] Lutz EM,Shen S.Structure of the human VIPR2 sene for vasoactive intestinal peptide receptor type?[J].FEBS Lett,1999,458:197-203.
[12] Gaudin P,Maoret JJ.Constitutive activation of the human vasoactive intestinal peptide 1 receptor,a member of the new class Ⅱ family of G protein-coupled receptors[J].J Biol Chem,1998,273 (9):4990-4996.
[13] Reubi JC.In vitro identification of vasoactive intestinal peptide receptors in human tumors:implications for tumor imaging[J].J Nucl Med,1995,36(10):1846-1895.
[14] Reubi JC,Lamberts ST.Receptor imaging of human diseases using radiolabeled peptides[J].J Recept Signal Transduct Res,1995,15(1-4):379-392.
[15] ReubiJC,Waser B.Receptor autoradiogrphic evaluation of cholecystokinin,neurotensin,somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples:Where are they really located?[J].Int J Cancer,1999,81(3):376-386.
[16] Virgolini I.Vasoactive intestinal peptide receptor scintigraphy[J].J Nucl Med,1995,36(10):1732-1739.
[17] Virgolini I,Raderer M.Vasoactive intestinal peptide receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumor[J].N Engl J Med,1994,331(17):1116-1121.
[18] Virgolini I,Raderer M.Iodine-123-vasoactive intestinal peptide receptor scanning up-to-date of imaging results in patients with adeocarcinomas and endocrine tumor of the gastrointestinal tract[J].Nucl Med Biol,1996,23(6):685-692.
[19] Pallela VR,Thakur ML.99Tcm-labeled vasoactive intestinal peptide receptor agonist:functional studies[J].J Nucl Med,1999,40(2):352-360.

相似文献/References:

[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
 He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
 Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
 Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
 Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
 zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[6]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
 Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[7]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
 Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[8]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
 Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[9]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
 Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[10]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
 Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]

备注/Memo

备注/Memo:
收稿日期:2000/5/11。
作者简介:王雪鹃(1974-),女,吉林长春人,北京大学临床肿瘤医院核医学科硕士研究生,主要从事肿瘤受体显像研究。;张梅颖(1944-),女,四川南充人,北京大学临床肿瘤医院副院长、核医学科主任、教授,主要研究肿瘤导向药物的研制及临床应用。;林保和(1956-),男,广东惠乐人,北京大学临床肿瘤医院核医学科助理研究员,主要研究肿瘤放免显像、肿瘤多药耐药的检测。
更新日期/Last Update: 1900-01-01